A mitochondrial 'geropeptide' kept very old mice moving and living longer — in company data presented in Berlin

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Eos SENOLYTIX builds on the foundation of SS-31 (elamipretide) — the four-amino-acid peptide that became the first FDA-approved mitochondria-targeted therapy — with MitoXcel geropeptides designed to find cells whose mitochondrial membrane potential has faded with age, restore their function, and progressively clear senescent cells. Berlin was where the company put its flagship candidate's mouse data in front of the field.

What did the aged-mouse data show?

Per Longevity.Technology's report of the keynote: in naturally aged mice, PTC-2105 improved survival at 25 mg/kg (log-rank p=0.0142) and produced dose-dependent gains on a Functional Composite Index; in aged high-fat-diet mice it cut the urinary albumin-to-creatinine ratio by roughly 70%, a kidney-stress signal; and inflammatory markers IL-6, TNF-alpha and CXCL10 fell. Company filings add that in one ongoing study, 40% of mice on the 25 mg/kg weekly dose remained alive and active at 146 weeks, past the point where all saline controls had died — and that PTC-2105 blunted the late-life lean-mass loss seen with semaglutide in aged mice.

Why is the field reading this with raised eyebrows as well as interest?

Because of how the data arrived: an industry keynote, company-generated, not peer-reviewed, with several headline claims reported without group sizes or full statistics, and some monitored arms of only 3–5 animals. The company's own ambassador animal — 'Speedy,' a mouse filmed moving energetically at 167 weeks — is a single animal, not evidence. None of that makes the data false; it makes it unfinished. Independent replication and, eventually, human trials are the tests that count.

What happens next for PTC-2105?

Eos is developing PTC-2105 first for sarcopenia and sarcopenic obesity and is advancing it toward first-in-human studies. A larger follow-up mouse study (SEL-082, 180 animals, including comparisons against semaglutide and retatrutide) is due to complete around the end of 2027. Until human data exist, PTC-2105 belongs in the same honest category as every mitochondrial geropeptide before it: a mechanistically coherent idea with encouraging mouse numbers, awaiting the only verdict that matters.

Where the evidence stands

• Established: SS-31/elamipretide, the peptide lineage PTC-2105 builds on, is an FDA-approved mitochondria-targeted therapy (for Barth syndrome); mitochondrial membrane potential declines with age and senescent-cell burden drives inflammation.
• Contested: Company-generated, non-peer-reviewed data presented at the World Congress on Targeting Mitochondria (Berlin, Oct 22, 2026) report improved survival (p=0.0142 at 25 mg/kg), function, kidney-stress and inflammatory markers in aged mice — with small monitored arms (3–5 animals in places) and incomplete statistics for several claims, as the reporting itself notes.
• Absent: Peer-reviewed publication, independent replication, and any human safety or efficacy data for PTC-2105.